Fundraising Fox
Epiliquid
Founded 2021 · 9 employees on LinkedIn · 2 known investors
Find your way into Epiliquid
Sign up to find every way you can get introduced to Epiliquid
- Your email: who you already know at Epiliquid, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Epiliquid team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Epiliquid develops blood-based molecular tests for cancer detection and differential diagnosis using a platform that combines AI-driven methylation biomarker discovery, patented native-DNA assay chemistry, and PCR-based readout. Its technology measures multiple methylation biomarkers in a single PCR reaction and runs on the qPCR and digital PCR instruments clinical laboratories already use, serving precision oncology.
Investors · 2
Founder mafia
2 people who came through Epiliquid went on to found or lead other companies.
Frequently asked questions
- What does Epiliquid do?
- Epiliquid develops blood-based molecular tests for cancer detection and differential diagnosis using a platform that combines AI-driven methylation biomarker discovery, patented native-DNA assay chemistry, and PCR-based readout. Its technology measures multiple methylation biomarkers in a single PCR reaction and runs on the qPCR and digital PCR instruments clinical laboratories already use, serving precision oncology.
- Who are Epiliquid's investors?
- Epiliquid's investors include AIR Capital, CITES.